Dr. Reddy's Laboratories

Dr Reddys shares tumble nearly 9 pc to hit 52-week low post-Q1 earnings announcement

Dr Reddy’s Q1 profit falls 69% as semaglutide issue and lenalidomide loss hit earnings

From generics to innovation: India pharma’s next growth story takes centre stage on Nikhil Kamath’s WTF

Nikhil Kamath Brings Together Pharma Veterans to Decode Indias Evolving Healthcare Landscape

Dr Reddy’s Q4 profit falls 86 per cent on weak North America sales

Money is an outcome, not the goal: Dr Reddy’s GV Prasad

G.V. Prasad

Biosimilars & innovation are Dr. Reddy’s growth pill: Generics to remain core business, says co-Chairman &

Dr Reddy’s close to Canada approval for generic weight loss drug: GV Prasad

Dr Reddy’s says Wegovy copycat to be priced competitively, with 50–60% discounts feasible

G. V. Prasad, Dr. Reddy’s Laboratories

India as a pharma innovation hub: An interview with Dr. Reddy’s G. V. Prasad